Table 3 Ex vivo stability data for doxorubicin (DOX)
Conditions | LQC (2.90Â ng/ml) | HQC (2000.00Â ng/ml) |
|---|---|---|
Long term stability; recovery (ng) after storage (− 40 °C) | ||
 Previous day | 2.83 ± 0.05 | 1989.04 ± 5.16 |
 30th day | 2.79 ± 0.04 (98.59%) | 1951.78 ± 19.12 (98.13%) |
Freeze–thaw stress; recovery (ng) after freeze–thaw cycles (− 40 to 25 °C) | ||
 Pre-cycle | 2.84 ± 0.03 | 1988.10 ± 4.19 |
 First cycle | 2.80 ± 0.04 (98.59%) | 1976.19 ± 12.91 (99.40%) |
 Second cycle | 2.78 ± 0.04 (97.88%) | 1972.54 ± 13.16 (99.22%) |
 Third cycle | 2.74 ± 0.05 (96.48%) | 1966.44 ± 13.67 (98.91) |
Heating–cooling stress; recovery (ng) after heating–cooling cycles (50–4 °C) | ||
 Pre-cycle | 2.85 ± 0.03 | 1989.09 ± 5.90 |
 First cycle | 2.80 ± 0.04 (98.25%) | 1981.61 ± 11.95 (99.62%) |
 Second cycle | 2.76 ± 0.03 (96.84%) | 1974.01 ± 12.04 (99.24%) |
 Third cycle | 2.72 ± 0.03 (95.44%) | 1963.02 ± 13.02 (98.69%) |
Bench top stability; recovery (ng) at room temperature (25 °C) | ||
 0 h | 2.84 ± 0.03 | 1988.49 ± 11.01 |
 24 h | 2.80 ± 0.05 (98.59%) | 1969.10 ± 12.31 (99.02%) |
Post processing stability; recovery (ng) after storage in auto sampler (4 °C) | ||
 0 h | 2.85 ± 0.03 | 1979.02 ± 7.91 |
 24 h | 2.81 ± 0.04 (99.60%) | 1962.01 ± 14.02 (99.14%) |